Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: J Allergy Clin Immunol Pract. 2020 Mar 7;8(8):2617–2627.e4. doi: 10.1016/j.jaip.2020.02.032

FIGURE 3.

FIGURE 3.

(A) Exacerbation frequency and (B) annualized rate of exacerbations (mean ± SEM) at the end of follow-up in latent classes 1 (multiple sensitization with partially reversible airflow limitation), 2 (multiple sensitization with reversible airflow limitation), 3 (lesser sensitization with reversible airflow limitation), 4 (multiple sensitization with normal lung function), and 5 (lesser sensitization with normal lung function).